Search Result

Results for "

PI3Kα IC50

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (17) Apoptosis (37) ATM/ATR (3) Autophagy (8) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (1) c-Myc (1) Cadherin (1) Casein Kinase (2) Caspase (1) CD3 (1) CDK (5) DNA-PK (7) Dopamine Receptor (3) EGFR (2) Epigenetic Reader Domain (5) ERK (2) GLUT (1) HDAC (5) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HSP (1) Interleukin Related (1) Isotope-Labeled Compounds (1) MAP4K (1) MEK (3) Mitochondrial Metabolism (1) MMP (1) mTOR (52) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) PAK (1) Paraptosis (1) Parasite (1) PARP (1) PD-1/PD-L1 (1) PERK (3) Phosphatase (2) PI3K (141) PI4K (3) PPAR (1) PROTACs (3) Ras (4) Reactive Oxygen Species (ROS) (2) Reference Standards (12) SARS-CoV (1) Syk (1) VEGFR (1) Virus Protease (1) Wnt (1)
By Research Areas:	Cancer (138) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (8)

By Targets:

Akt (17)

Apoptosis (37)

ATM/ATR (3)

Autophagy (8)

Bacterial (1)

Bcl-2 Family (1)

Bcr-Abl (1)

c-Myc (1)

Cadherin (1)

Casein Kinase (2)

Caspase (1)

CD3 (1)

CDK (5)

DNA-PK (7)

Dopamine Receptor (3)

EGFR (2)

Epigenetic Reader Domain (5)

ERK (2)

GLUT (1)

HDAC (5)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HSP (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

MAP4K (1)

MEK (3)

Mitochondrial Metabolism (1)

MMP (1)

mTOR (52)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

PAK (1)

Paraptosis (1)

Parasite (1)

PARP (1)

PD-1/PD-L1 (1)

PERK (3)

Phosphatase (2)

PI3K (141)

PI4K (3)

PPAR (1)

PROTACs (3)

Ras (4)

Reactive Oxygen Species (ROS) (2)

Reference Standards (12)

SARS-CoV (1)

Syk (1)

VEGFR (1)

Virus Protease (1)

Wnt (1)

By Research Areas:

Cancer (138)

Cardiovascular Disease (1)

Infection (7)

Inflammation/Immunology (11)

Metabolic Disease (5)

Neurological Disease (8)

149

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10108

LY294002 Maximum Cited Publications 1120 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of *PI3K* with *IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ* and PI3Kβ, respectively . LY294002 also inhibits CK2 with an *IC₅₀* of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an *IC₅₀* of 1.4 μM. LY294002 is an apoptosis activator ^[3].

HY-101562

Inavolisib 5+ Cited Publications GDC-0077; RG6114	PI3K Apoptosis	Cancer
Inavolisib (GDC-0077) is a potent, orally active, and selective *PI3Kα* inhibitor (IC₅₀=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer .

HY-10681

Gedatolisib 5 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of *PI3Kα, PI3Kγ, and mTOR* with *IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1* and mTORC2 .

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an *IC₅₀* of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-15346

Copanlisib 30+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with *IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ* and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 30+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with *IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ* and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-159852

BBO-10203	PI3K Ras Akt	Cancer
BBO-10203 is a potent inhibitor of *PI3Kα* and KRAS ^G12C, selectively and covalently binding to Cys242 in the RAS-Binding Domain of *PI3Kα, and inhibiting both the GTP-bound and GDP-bound states of KRAS ^G12C* with an *IC₅₀* of 0.031 nM and an *EC₅₀* of 0.02 nM. BBO-10203 disrupts the interaction between RAS isoforms and *PI3Kα, leading to the inhibition of RAS-mediated PI3Kα* activation, and reduces pERK expression, cell growth, and induces G₁ arrest and apoptosis. BBO-10203 can be used for the research of breast cancer, colorectal cancer, and non-small cell lung cancer .

HY-154848

UCL-TRO-1938 3 Publications Verification	PI3K Akt	Cardiovascular Disease Neurological Disease Cancer
UCL-TRO-1938 is a potent small molecule allosteric activator of *PI3Kα* with an *EC₅₀* value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush ^[3] .

HY-12868

Bimiralisib 4 Publications Verification PQR309	PI3K mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR* inhibitor with *IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ* and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor.

HY-12513

Samotolisib 5+ Cited Publications LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with *IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1*/2 at low nanomolar concentrations .

HY-12046

PIK-93 5+ Cited Publications	PI4K PI3K Virus Protease	Cancer
PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with *IC₅₀* of 19 nM, and also inhibits PI3Kγ and *PI3Kα* with *IC₅₀* of 16 nM and 39 nM, respectively.

HY-15174

Dactolisib Tosylate 65+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual *PI3K* and mTOR kinase inhibitor with *IC₅₀* values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-12330

AZD8186 5+ Cited Publications	PI3K	Cancer
AZD8186 is a *PI3K* inhibitor, which potently inhibits PI3Kβ (IC₅₀=4 nM) and PI3Kδ (IC50₅₀=12 nM) with selectivity over PI3Kα (IC₅₀=35 nM) and PI3Kγ (IC₅₀=675 nM).

HY-173405

VVD-699	Ras PI3K Akt	Cancer
VVD-699 is a covalent blocker of the RAS-p110α interaction with oral activity. VVD-699 inhibits activation of *PI3Kα* (IC₅₀: 104 nM in H358 cells) . VVD-699 inhibits phosphorylated AKT. VVD-699 can be used for the research of KRAS mutant/amplified cancer .

HY-16596

CNX-1351	PI3K	Cancer
CNX-1351 is a potent and isoform-selective targeted covalent *PI3Kα* inhibitor with *IC₅₀* of 6.8 nM.

HY-10683

PKI-402 10+ Cited Publications	PI3K mTOR	Cancer
PKI-402 is a selective, reversible, ATP-competitive inhibitor of *PI3K, including PI3K-α* mutants, and mTOR (IC₅₀=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).

HY-101146

SF2523 2 Publications Verification	PI3K Epigenetic Reader Domain DNA-PK	Cancer
SF2523 is a highly selective and potent inhibitor of *PI3K* with *IC₅₀s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK*, BRD4 and mTOR, respectively.

HY-16526

Pilaralisib 5 Publications Verification XL-147; SAR245408	PI3K	Cancer
Pilaralisib (XL147; SAR245408) is a potent and highly selective class I *PI3Ks inhibitor with IC₅₀s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα*, PI3Kβ, PI3Kγ, and PI3Kδ.

HY-13334A

BGT226 5 Publications Verification NVP-BGT226	PI3K mTOR Autophagy	Cancer
BGT226 (NVP-BGT226) is a *PI3K* (with *IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ* and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-15856B

Flupentixol dihydrochloride 2 Publications Verification Flupenthixol dihydrochloride	Dopamine Receptor PI3K Apoptosis	Neurological Disease Cancer
Flupentixol is an orally active D₁/D₂ dopamine receptor antagonist and new *PI3K* inhibitor (PI3Kα *IC₅₀*=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research ^[3].

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with *IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2* as well as mTORC1.

HY-15466

Izorlisib 3 Publications Verification CH5132799	PI3K	Cancer
Izorlisib (CH5132799) is a selective class I *PI3K* inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an *IC₅₀* of 14 nM.

HY-100385

Brevianamide F 2 Publications Verification Cyclo(L-Pro-L-Trp)	PI3K Bacterial	Infection
Brevianamide F (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity. Brevianamide F shows potent *PI3Kα* inhibitory activity with an *IC₅₀* of 4.8 μM .

HY-12034

WYE-354 5+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
WYE-354 is an ATP-competitive mTOR inhibitor with an *IC₅₀* of 5 nM. WYE-354 also inhibits *PI3Kα* and PI3Kγ with *IC₅₀s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both mTORC1* and mTORC2. WYE-354 induces autophagy activation in vitro ^[3].

HY-13431

KU-0060648 4 Publications Verification	DNA-PK PI3K mTOR	Cancer
KU-0060648 is a dual inhibitor of *PI3K* and DNA-PK with *IC₅₀s of 4 nM, 0.5 nM, 0.1 nM, 0.594 nM and 8.6 nM for PI3Kα*, PI3Kβ, PI3Kγ, PI3Kδ and DNA-PK, respectively .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR* inhibitor with *IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα*, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-13334

BGT226 maleate 5 Publications Verification NVP-BGT226 maleate	PI3K mTOR Autophagy Apoptosis	Cancer
BGT226 (NVP-BGT226 maleate) is a *PI3K* (with *IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ* and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-13531

AS-604850 1 Publications Verification	PI3K	Cancer
AS-604850 is a potent, selective and ATP-competitive PI3Kγ inhibitor with an *IC₅₀* value of 0.25 μM and a K_i value of 0.18 μM. AS-604850 shows isoform selective inhibitor of PI3Kγ with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively .

HY-12869

AZD-8835 1 Publications Verification	PI3K	Cancer
AZD8835 is a potent and selective inhibitor of *PI3Kα* and PI3Kδ with *IC₅₀*s of 6.2 and 5.7 nM, respectively.

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective *PI3Kα* inhibitor with an *IC₅₀* of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for *PI3Kα* and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive mTOR inhibitor with an *IC₅₀* of 7 nM. WYE-687 concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits *PI3Kα* and PI3Kγ with *IC₅₀*s of 81 nM and 3.11 μM, respectively.

HY-13333

NVP-BAG956 BAG 956	PI3K	Cancer
NVP-BAG956 is an ATP-competitive *PI3K* inhibitor with *IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα*, PI3Kγ and PI3Kβ, respectively.

HY-162713

MTX-531	EGFR PI3K PPAR	Cancer
MTX-531 is an oral drug that inhibits EGFR (with an *IC₅₀* of 14.7 nM) and *PI3K* (with *IC₅₀* values of 6.4, 233, 8.3, and 1.1 nM for *PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ* respectively), and it has anti-tumor effects. MTX-531 also acts as a weak agonist of PPARγ, with an *IC₅₀* of 2.5 µM, helping to alleviate hyperglycemia induced by PI3K inhibitors .

HY-174461

PROTAC PI3Kα degrader-1	PROTACs PI3K	Cancer
PROTAC PI3Kα degrader-1 is a *PI3Kα* PROTAC degrader (DC₅₀ = 0.08 μM), demonstrating good selectivity for PI3Kα degradation over PI3Kβ, PI3Kγ, and PI3Kδ. PROTAC PI3Kα degrader-1 effectively degrades PI3Kα in a time- and concentration-dependent, over PI3Kβ, PI3Ky and PI3Kδ, and potently inhibited the phosphorylation of AKT at the Ser473site. PROTAC PI3Kα degrader-1 shows significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models. (Pink: PI3Kα ligand : (HY-174798), Blue: E3 ligase CRBN Ligand (HY-10984), Black: Linker, E3 ligase ligand-linker conjugate (HY-W940885)) .

HY-118712

WYE-23	mTOR	Cancer
WYE-23 is a mTOR inhibitor, and *IC₅₀* is 0.45 nM. It is selective to PI3Kα and *IC₅₀* is 661 nM. WYE-23 has antitumor activity .

HY-124036

DS-7423	PI3K mTOR	Cancer
DS-7423 is a dual *PI3K* and mTOR inhibitor, with *IC₅₀* values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

HY-136198

SRX3207	Syk PI3K	Cancer
SRX3207 is an orally active and first-in-class dual *Syk/PI3K* inhibitor, with *IC₅₀* values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression .

HY-112443

AZD3458	PI3K	Metabolic Disease Inflammation/Immunology Cancer
AZD3458 is a potent and remarkably selective PI3Kγ inhibitor with *pIC₅₀s of 9.1, 5.1, <4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ*, respectively .

HY-143404

PI3K-IN-30 3 Publications Verification	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with *IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα*, PI3Kβ, PI3Kγ and PI3Kδ, respectively .

HY-110109

ETP-45658	PI3K DNA-PK mTOR	Cancer
ETP-45658 is a potent *PI3K* inhibitor, with *IC₅₀s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3Kα, PI3Kδ, PI3Kβ* and PI3Kγ, respectively. ETP-45658 also can inhibit DNA-PK (IC₅₀=70.6 nM) and mTOR (IC₅₀=152.0 nM). ETP-45658 can be used for the research of cancer .

HY-100470

NSC781406 2 Publications Verification	PI3K mTOR	Cancer
NSC781406 is a highly potent *PI3K* and mTOR inhibitor with an *IC₅₀* of 2 nM for PI3Kα.

HY-150618

PI3Kα-IN-9 1 Publications Verification	PI3K Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with *IC₅₀* values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively. PI3Kα-IN-9 has antiproliferative activity and induces apoptosis. PI3Kα-IN-9 can be used for cancer research .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with *IC₅₀* values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-149669

PH14	PI3K HDAC Apoptosis	Cancer
PH14 is a dual *PI3K/HDAC* inhibitor with *IC₅₀* values of 20.3 nM and 24.5 nM for *PI3Kα* and *HDAC3, respectively. PH14 has antiproliferative activity and also induces apoptosis* in Jeko-1 cells. PH14 can be used in cancer research, such as lymphoma .

HY-10681R

Gedatolisib (Standard)	PI3K mTOR Reference Standards	Cancer
Gedatolisib (Standard) is the analytical standard of Gedatolisib. This product is intended for research and analytical applications. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

HY-10620

PI3K-IN-22	PI3K mTOR	Cancer
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has *IC₅₀s of 0.9, 0.6 nM for PI3Kα* and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .

HY-131345

PI3Kα-IN-4	PI3K	Cancer
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of *PI3Kα, with an IC₅₀* of 1.8 nM. PI3Kα-IN-4 has antitumor activity .

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of *mTOR>/b< (IC₅₀)=0.08* nM. mTOR inhibitor WYE-28 inhibits *PI3Kα* with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min .**

HY-15174R

Dactolisib Tosylate (Standard) BEZ235 Tosylate (Standard); NVP-BEZ 235 Tosylate (Standard)	PI3K mTOR Autophagy Reference Standards	Cancer
Dactolisib (Tosylate) (Standard) is the analytical standard of Dactolisib (Tosylate). This product is intended for research and analytical applications. Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-15856A

Flupentixol Flupenthixol	Dopamine Receptor PI3K Apoptosis	Neurological Disease
Flupentixol is an orally active D₁/D₂ dopamine receptor antagonist and new *PI3K* inhibitor (PI3Kα *IC₅₀*=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research ^[3].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100385

Brevianamide F 2 Publications Verification Cyclo(L-Pro-L-Trp)	Infection Alkaloids Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Endogenous metabolite Disease Research Fields Indole Alkaloids Source Classification	PI3K Bacterial
Brevianamide F (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity. Brevianamide F shows potent *PI3Kα* inhibitory activity with an *IC₅₀* of 4.8 μM .

Cat. No.	Product Name	Chemical Structure

HY-10681S

Gedatolisib-d8
Gedatolisib-d₈ (PKI-587-d₈) is the deuterium labeled Gedatolisib (HY-10681). Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks